{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigjaev6ywg7vzrsc7ik7rjmlrgs5llhb2f3667yujo3flfuy2u6hi",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mghda6ctr6f2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiceelzerfvf44yalnuzldlet5jm2x5g52k7d4d6fxbcr6dicd6xca"
    },
    "mimeType": "image/jpeg",
    "size": 77243
  },
  "path": "/2026/03/06/glp-1-weight-loss-pill-development-status-report-alex-hogan/?utm_campaign=rss",
  "publishedAt": "2026-03-06T09:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "STATus Report",
    "biotechnology",
    "Obesity",
    "Pharmaceuticals"
  ],
  "textContent": "In this week’s STATus Report, host Alex Hogan explains why weight loss pills were so much harder to develop than injectables.",
  "title": "How the ‘holy grail’ weight loss pill became a reality, and what comes next",
  "updatedAt": "2026-03-06T13:46:14.000Z"
}